MYD88 and cancer: In high-grade serous ovarian cancer (HGSOC), high expression of MyD88 is associated with advanced stage (p < 0.001) cancer and moderately associated with shorter overall survival (HR: 1.13; 95% CI: 1.01–1.26; p = 0.04).